✦ LIBER ✦

Biokinetics of yttrium-90–labeled huBrE-3 monoclonal antibody

✍ Scribed by Timothy K. Johnson; William Cole; Robert A. Quaife; James L. Lear; Roberto L. Ceriani; Roy B. Jones; Pablo J. Cagnoni

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 204 KB
Volume: 94
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.10292

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Labeling of monoclonal antibody conjugat

Labeling of monoclonal antibody conjugates with 90Y

✍ Cecilia Motta-Hennessy; Robert M. Sharkey; David M. Goldenberg 📂 Article 📅 1991 🏛 Elsevier Science ⚖ 659 KB

An anti-carcinoembryonic antigen (CEA) antibody, NP-4, was labeled with 90Y using p-isothiocyanatobenzyl DTPA (SCN-Bz-DTPA) and its derivatives 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), 1-(2)-methyl-4- isothiocyanatobenzyl-DTPA (MX-DTPA) as the

Advantage of yttrium-90-labeled over iod

Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft

✍ Rhona Stein; Susan Chen; Sara Haim; David M. Goldenberg 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

BACKGROUND. The purpose of this investigation was to compare the therapeutic Rhona Stein, Ph

The production and biological distributi

The production and biological distribution of yttrium-90 labelled antibodies

✍ A.T.M. Vaughan; A. Keeling; S.C.S. Yankuba 📂 Article 📅 1985 🏛 Elsevier Science ⚖ 364 KB

Difference in the biodistribution of ind

Difference in the biodistribution of indium and yttrium labelled monoclonal antibodies

✍ O.A. Gansow; M.W. Brechbiel; S. Mirzadeh; M. Roselli; D. Colcher; A. Raubitschek 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 113 KB 👁 1 views

Use of an yttrium 90 labeled antibody fo

Use of an yttrium 90 labeled antibody for the treatment of human colon cancer xenografts in nude mice

✍ Craig S. Heacock; Ann M. Blake; Christopher J. D'Aleo; Vernon L. Alvarez 📂 Article 📅 1988 🏛 Elsevier Science ⚖ 60 KB

Combined 90Yttrium-DOTA-labeled PAM4 ant

Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft

✍ David V. Gold; David E. Modrak; Keith Schutsky; Thomas M. Cardillo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 132 KB

## Abstract We have examined the application of ^90^Y‐DOTA‐cPAM4, anti‐MUC1 IgG, in combination with the front‐line drug gemcitabine as a potential therapeutic for pancreatic cancer. Athymic nude mice bearing CaPan1 human pancreatic cancer xenografts were administered 2 mg of gemcitabine on days 0,